Engages in the development of personalized therapies addressing unmet medical needs in oncology.
Aptose Biosciences Inc. is a forward-looking clinical-stage biotechnology company focused on discovering and developing personalized therapies to address critical unmet medical needs in oncology, primarily operating within the United States. Established in 1986 and headquartered in Toronto, Canada, Aptose Biosciences is dedicated to advancing innovative treatments that target various cancers. The company's diverse clinical pipeline includes APTO-253, currently undergoing Phase 1a/b trials for patients with relapsed or refractory blood cancers such as acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Additionally, HM43239 is progressing through Phase 1/2 trials for the treatment of relapsed or refractory AML.
Aptose Biosciences is also developing luxeptinib, undergoing Phase 1a/b trials for B-cell malignancies including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, alongside applications for AML and HR MDS. The company's innovative pipeline extends to APL-581, a dual inhibitor targeting bromodomain and extra-terminal domain motif proteins and kinases. Aptose Biosciences collaborates with industry leaders such as CrystalGenomics, Inc. and OHM Oncology to further advance its therapeutic programs and expand treatment options for cancer patients.
Formerly known as Lorus Therapeutics Inc., Aptose Biosciences rebranded in August 2014 to reflect its focus on cutting-edge biotechnological advancements. With a strong commitment to scientific innovation and clinical excellence, Aptose Biosciences continues to drive progress in oncology research, aiming to deliver transformative therapies that improve patient outcomes worldwide.